This was the stock's second consecutive day of losses.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...

1 Day CRBP -2.32% DJIA -0.07% Russell 2K 0.00% Health Care/Life Sciences -0.02% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 1.54% to $9.88 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite ...